The role of cytochromes P450 and aldo-keto reductases in prognosis of breast carcinoma patients

Medicine (United States)

Volumn 93, Issue 28, 2014, Pages e255-

  Hlaváč, Viktor ^a,b   Brynychová, Veronika ^a,b   Václavíková, Radka ^a   Ehrlichová, Marie ^a,b   Vrána, David ^a,c   Pecha, Václav ^d   Trnková, Markéta ^d   Kodet, Roman ^d   Mrhalová, Marcela ^d   Kubáčková, Kateřina ^d   Gatěk, Jiří ^e,f   Vážan, Petr ^g   Souček, Pavel ^a  

^a NATIONAL INSTITUTE OF PUBLIC HEALTH   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c PALACKÝ UNIVERSITY   (Czech Republic)

^d UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^e Department of Surgery Atlas Hospital   (Czech Republic)

^f TOMAS BATA UNIVERSITY IN ZLIN   (Czech Republic)

^g VELAB Ltd   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE REDUCTASE; ALDO KETO REDUCTASE; ALDO KETO REDUCTASE1 C1; ALDO KETO REDUCTASE1 C2; ALDO KETO REDUCTASE1 C3; ALDO KETO REDUCTASE1 C4; ALDO KETO REDUCTASE7 A3; CARBONYL REDUCTASE; CARBONYL REDUCTASE 1; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2S1; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; CYTOCHROME P4502W1; OXIDOREDUCTASE; PACLITAXEL; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VOLTAGE GATED POTASSIUM CHANNEL; RNA;

ARTICLE; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DOWN REGULATION; FEMALE; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GENE SILENCING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IN VITRO STUDY; MAJOR CLINICAL STUDY; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT RESPONSE; UPREGULATION; BIOSYNTHESIS; BREAST TUMOR; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; PROGNOSIS; PROSPECTIVE STUDY; TUMOR CELL CULTURE;

ALDEHYDE REDUCTASE; BREAST NEOPLASMS; CELL PROLIFERATION; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOBLOTTING; PROGNOSIS; PROSPECTIVE STUDIES; REAL-TIME POLYMERASE CHAIN REACTION; RNA, NEOPLASM; TUMOR CELLS, CULTURED;

EID: 84920114444     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000000255     Document Type: Article

References (43)

1. Ferlay J, Shin HR, Bray F, et al. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10. Lyon, France: International Agency for Research on Cancer; 2010.
2. Baguley BC. Multiple drug resistance mechanisms in cancer. Mol Biotechnol. 2010; 46: 308-316.
3. Johansson I, Ingelman-Sundberg M. Genetic polymorphism and toxicology with emphasis on cytochrome P450. Toxicol Sci. 2011; 120: 1-13.
4. Roy P, Yu LJ, Crespi CL, et al. Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNAexpressed activities and liver microsomal P-450 profiles. Drug Metab Dispos. 1999; 27: 655-666.
5. Chang TK, Weber GF, Crespi CL, et al. Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res. 1993; 53: 5629-5637.
6. Rodriguez-Antona C, Gomez A, Karlgren M, et al. Molecular genetics and epigenetics of the cytochrome P450 gene family and its relevance for cancer risk and treatment. Hum Genet. 2010; 127: 1-17.
7. Rahman A, Korzekwa KR, Grogan J, et al. Selective biotransformation of taxol to 6a-hydroxytaxol by human cytochrome P450 2C8. Cancer Res. 1994; 54: 5543-5546.
8. Shou M, Korzekwa KR, Krausz KW, et al. Role of human cytochrome P450 3A4 and 3A5 in the metabolism of Taxotere and its derivatives: enzyme specificity, interindividual distribution and metabolic contribution in human liver. Pharmacogenetics. 1998; 8: 391-401.
9. Komatsu T, Yamazaki H, Shimada N, et al. Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000; 28: 1457-1463.
10. Sim SC, Kacevska M, Ingelman-Sundberg M. Pharmacogenomics of drug-metabolizing enzymes: a recent update on clinical implications and endogenous effects. Pharmacogenomics J. 2013; 13: 1-11.
11. Iscan M, Klaavuniemi T, Coban T, et al. The expression of cytochrome P450 enzymes in human breast tumours and normal breast tissue. Breast Cancer Res Treat. 2001; 70: 47-54.
12. Modugno F, Knoll C, Kanbour-Shakir A, et al. A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003; 82: 191-197.
13. Murray GI, Patimalla S, Stewar KN, et al. Profiling the expression of cytochrome P450 in breast cancer. Histopathology. 2010; 57: 202-211.
14. Karlgren M, Gomez A, Stark K, et al. Tumor-specific expression of the novel cytochrome P450 enzyme, CYP2W1. Biochem Biophys Res Commun. 2006; 341: 451-458.
15. Edler D, Stenstedt K, Ohrling K, et al. The expression of the novel CYP2W1 enzyme is an independent prognostic factor in colorectal cancer - A pilot study. Eur J Cancer. 2009; 45: 705-712.
16. Barski OA, Tipparaju SM, Bhatnagar A. The aldo-keto reductase superfamily and its role in drug metabolism and detoxification. Drug Metab Rev. 2008; 40: 553-624.
17. Wermuth B, Platts KL, Seidel A, et al. Carbonyl reductase provides the enzymatic basis of quinone detoxication in man. Biochem Pharmacol. 1986; 35: 1277-1282.
18. Thorn CF, Oshiro C, Marsh S, et al. Adriamycin pathways: pharmacodynamics and adverse effects. Pharmacogenet Genomics. 2011; 21: 440-446.
19. Hlaváč V, Brynychová V, Václavíková R, et al. The expression profile of ABC transporter genes in breast carcinoma. Pharmacogenomics. 2013; 14: 515-529.
20. Hubackova M, Vaclavikova R, Ehrlichova M, et al. Association of superoxide dismutases and NAD(P)H oxidoreductases with prognosis of patients with breast carcinomas. Int J Cancer. 2012; 130: 338-348.
21. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92: 205-216.
22. Bustin SA, Benes V, Garson JA, et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem. 2009; 55: 611-622.
23. Anzenbacher P, Souček P, Gut I, et al. Presence and activity of cytochrome P-450 isoforms in minipig liver microsomes: comparison with human liver samples. Drug Metab. Dispos. 1998; 26: 56-59.
24. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Royal Statist Soc B. 1995; 57: 289-300.
25. Bièche I, Girault I, Urbain E, et al. Relationship between intratumoral expression of genes coding for xenobiotic-metabolizing enzymes and benefit from adjuvant tamoxifen in estrogen receptor alpha-positive postmenopausal breast carcinoma. Breast Cancer Res. 2004; 6: R252-R263.
26. Tozlu S, Girault I, Vacher S, et al. Identification of novel genes that co-cluster with estrogen receptor alpha in breast tumor biopsy specimens, using a large-scale real-time reverse transcription-PCR approach. Endocr Relat Cancer. 2006; 13: 1109-1120.
27. Lo R, Burgoon L, Macpherson L, et al. Estrogen receptor-dependent regulation of CYP2B6 in human breast cancer cells. Biochim Biophys Acta. 2010; 1799: 469-479.
28. Schmidt R, Baumann F, Knüpfer H, et al. CYP3A4, CYP2C9 and CYP2B6 expression and ifosfamide turnover in breast cancer tissue microsomes. Br J Cancer. 2004; 90: 911-916.
29. Reyaul K, Thumar JK, Lundgren DH, et al. Differential protein expression profiles in estrogen receptor-positive and -negative breast cancer tissues using label-free quantitative proteomics. Genes Cancer. 2010; 1: 251-271.
30. Dunnwald LK, Rossing MA, Li CI. Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res. 2007; 9: R6.
31. Lewis MJ, Wiebe JP, Heathcote JG. Expression of progesterone metabolizing enzyme genes (AKR1C1, AKR1C2, AKR1C3, SRD5A1, SRD5A2) is altered in human breast carcinoma. BMC Cancer. 2004; 4: 27.
32. Ji Q, Aoyama C, Nien YD, et al. Selective loss of AKR1C1 and AKR1C2 in breast cancer and their potential effect on progesterone signaling. Cancer Res. 2004; 64: 7610-7617.
33. Veitch ZW, Guo B, Hembruff SL, et al. Induction of 1C aldoketoreductases and other drug dose-dependent genes upon acquisition of anthracycline resistance. Pharmacogenet Genomics. 2009; 19: 477-488.
34. Wu L, Hu X, Tang H, et al. Valid application of Western blotting. Mol Biol Rep. 2014; 41: 3517-3520.
35. Miyoshi Y, Ando A, Takamura Y, et al. Prediction of response to docetaxel by CYP3A4 mRNA expression in breast cancer tissues. Int J Cancer. 2002; 97: 129-132.
36. Miyoshi Y, Taguchi T, Kim SJ, et al. Prediction of response to docetaxel by immunohistochemical analysis of CYP3A4 expression in human breast cancers. Breast Cancer. 2005; 12: 11-15.
37. Kapucuoglu N, Coban T, Raunio H, et al. Immunohistochemical demonstration of the expression of CYP2E1 in human breast tumour and non-tumour tissues. Cancer Lett. 2003; 196: 153-159.
38. Kim SM, Acharya P, Engel JC, et al. Liver cytochrome P450 3A ubiquitination in vivo by gp78/autocrine motility factor receptor and C terminus of Hsp70-interacting protein (CHIP) E3 ubiquitin ligases: physiological and pharmacological relevance. J Biol Chem. 2010; 285: 35866-35877.
39. Olson RD, Mushlin PS, Brenner DE, et al. Adriamycin cardiotoxicity may be caused by its metabolite, adriamycinol. Proc Natl Acad Sci USA. 1988; 85: 3585-3589.
40. Lal S, Sandanaraj E, Wong ZW, et al. CBR1 and CBR3 pharmacogenetics and their influence on adriamycin disposition in Asian breast cancer patients. Cancer Sci. 2008; 99: 2045-2054.
41. López de Cerain A, Marín A, Idoate MA, et al. Carbonyl reductase and NADPH cytochrome P450 reductase activities in human tumoral versus normal tissues. Eur J Cancer. 1999; 35: 320-324.
42. Murakami A, Yakabe K, Yoshidomi K, et al. Decreased carbonyl reductase 1 expression promotes malignant behaviours by induction of epithelial mesenchymal transition and its clinical significance. Cancer Lett. 2012; 323: 69-76.
43. Murakami A, Fukushima C, Yoshidomi K, et al. Suppression of carbonyl reductase expression enhances malignant behaviour in uterine cervical squamous cell carcinoma: carbonyl reductase predicts prognosis and lymph node metastasis. Cancer Lett. 2011; 311: 77-84.